

Carlo Briguori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3403796/publications.pdf>

Version: 2024-02-01

90
papers

4,286
citations

201385

27
h-index

110170

64
g-index

92
all docs

92
docs citations

92
times ranked

4701
citing authors

#	ARTICLE	IF	CITATIONS
1	Paclitaxel versus sirolimus-coated balloon in the treatment of coronary in-stent restenosis. <i>Panminerva Medica</i> , 2023, 65, .	0.2	5
2	One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients. <i>Journal of the American Heart Association</i> , 2022, 11, e023454.	1.6	7
3	Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 707-716.	1.4	5
4	Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. <i>EuroIntervention</i> , 2022, 17, 1330-1339.	1.4	5
5	Dialysis Initiation in Patients With Chronic Coronary Disease and Advanced Chronic Kidney Disease in ISCHEMIA-CKD. <i>Journal of the American Heart Association</i> , 2022, 11, e022003.	1.6	6
6	DyeVert Contrast Reduction System Use in Patients Undergoing Coronary and/or Peripheral Angiography: A Systematic Literature Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2022, 9, 841876.	1.2	5
7	Nonpulsatile Systemic Flow During Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock. , 2022, , 100384.		0
8	Impact of a contrast media volume control device on acute kidney injury rate in patients with acute coronary syndrome. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 76-84.	0.7	13
9	Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI : TWILIGHT-SYNERGY. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 63-71.	0.7	6
10	Potential Utility of Cardiorenal Biomarkers for Prediction and Prognostication of Worsening Renal Function in Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 533-541.	0.7	11
11	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 444-456.	1.1	27
12	STENTYS coronary system: current status and future direction. <i>Minerva Cardiology and Angiology</i> , 2021, 69, 201-214.	0.4	0
13	Early P2Y ₁₂ Receptor Monotherapy Following Drug-Eluting Stenting: Is It Time to Give Up Aspirin?. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010880.	1.4	0
14	Urinary Dickkopf-3 and Contrast-Associated Kidney Damage. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2667-2676.	1.2	18
15	Myocardial hypoxic stress mediates functional cardiac extracellular vesicle release. <i>European Heart Journal</i> , 2021, 42, 2780-2792.	1.0	32
16	Tailored Versus Standard Hydration to Prevent Acute Kidney Injury After Percutaneous Coronary Intervention: Network Meta-Analysis. <i>Journal of the American Heart Association</i> , 2021, 10, e021342.	1.6	11
17	Device-related complications after Impella mechanical circulatory support implantation: an IMP-IT observational multicentre registry substudy. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 999-1006.	0.4	16
18	The "locking and dragging" technique a facilitated crossover balloon occlusion technique for complex iliofemoral anatomy in transcatheter aortic valve replacement. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E968-E970.	0.7	0

#	ARTICLE	IF	CITATIONS
37	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , 2019, 381, 2032-2042.	13.9	683
38	OCT Appraisal of Residual Thrombus Burden in Patients With STEMI Undergoing Intraprocedural Versus Post-Stenting Prolonged Bivalirudin Infusion. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 934-936.	2.3	3
39	Clinical expert consensus document on the use of percutaneous left ventricular assist support devices during complex high-risk indicated PCI. <i>International Journal of Cardiology</i> , 2019, 293, 84-90.	0.8	46
40	One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in patients presenting with acute myocardial infarction: Insight from the ULISSE registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 972-979.	0.7	5
41	Comparison of intra-procedural vs. post-stenting prolonged bivalirudin infusion for residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing: the MATRIX (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and angioX) OCT study. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 1418-1428.	0.5	5
42	Predictors of strut coverage of drug eluting stent implantation in diabetic patients- Is only on-clopidogrel platelet reactivity enough? Reply. <i>International Journal of Cardiology</i> , 2019, 283, 95.	0.8	1
43	Safety and Efficacy of Polymer-Free Drug-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007311.	1.4	30
44	Sirolimus-eluting BiOSS LIM dedicated bifurcation stent in the treatment of unprotected distal left main stenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 323-331.	0.7	5
45	Predictors of strut coverage of drug eluting stent implantation in diabetic patients. <i>International Journal of Cardiology</i> , 2019, 276, 61-65.	0.8	3
46	Mid-term outcomes after percutaneous interventions in coronary bifurcations. <i>International Journal of Cardiology</i> , 2019, 283, 78-83.	0.8	33
47	Left ventricular support during complex transradial percutaneous coronary intervention for complete revascularization. <i>Minerva Cardioangiologica</i> , 2019, 67, 348-355.	1.2	2
48	Elective Mechanical Circulatory Support in the Percutaneous Treatment of Patients With Combined Complex Coronary Artery Disease and Severe Aortic Valve Stenosis. <i>Journal of Invasive Cardiology</i> , 2019, 31, 52-56.	0.4	3
49	One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in all-comers population. Insight from the ULISSE registry (ULTImaster Italian multicenter all comerS Stent rEgistry). <i>International Journal of Cardiology</i> , 2018, 260, 36-41.	0.8	15
50	Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1231-1242.	1.2	32
51	Clinical outcomes with reservoir-based polymer-free amphilimus-eluting stents in real-world patients according to diabetes mellitus and complexity: The INVESTIG8 registry. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 884-891.	0.7	11
52	Persistent serum creatinine increase following contrast-induced acute kidney injury. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 1185-1191.	0.7	9
53	Outcomes of the amphilimus-eluting polymer-free stent for chronic total occlusion treatment. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 564-570.	0.6	1
54	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. <i>Lancet, The</i> , 2018, 392, 835-848.	6.3	215

#	ARTICLE	IF	CITATIONS
55	Midterm and one-year outcome of amphilimus polymer free drug eluting stent in patients needing short dual antiplatelet therapy. Insight from the ASTUTE registry (Amphilimus iTalian mUlticenTer) Tj ETQq1 1 0.78431 4 rgBT1/Overlook	0.8	10
56	Impact of statin therapy intensity on endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The REMEDY-EPC late study. International Journal of Cardiology, 2017, 244, 112-118.	0.8	10
57	Coronary artery bifurcation narrowing treated by Axxess stent implantation: The CARINAX registry. Catheterization and Cardiovascular Interventions, 2017, 89, E112-E123.	0.7	7
58	One-year clinical outcome of amphilimus polymer-free drug-eluting stent in diabetes mellitus patients. International Journal of Cardiology, 2016, 214, 113-120.	0.8	25
59	RenalGuard system in high-risk patients for contrast-induced acute kidney injury. American Heart Journal, 2016, 173, 67-76.	1.2	39
60	Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?. JACC: Cardiovascular Interventions, 2016, 9, 426-436.	1.1	135
61	RenalGuard System for the prevention of acute kidney injury in patients undergoing transcatheter aortic valve implantation. EuroIntervention, 2016, 11, e1658-e1661.	1.4	27
62	The STENTYSA® paclitaxel-eluting stent in the treatment of unprotected distal left main. Catheterization and Cardiovascular Interventions, 2015, 86, E131-9.	0.7	21
63	Contrast-induced acute kidney injury. Current Opinion in Nephrology and Hypertension, 2015, 24, 145-153.	1.0	23
64	Endothelial Progenitor Cells and Percutaneous Coronary Artery Intervention. Cardiovascular Drugs and Therapy, 2015, 29, 105-106.	1.3	0
65	Novel Approaches for Preventing or Limiting Events (Naples) III Trial. JACC: Cardiovascular Interventions, 2015, 8, 414-423.	1.1	45
66	Neutrophil Gelatinase-Associated Lipocalin and Contrast-Induced Acute Kidney Injury. Circulation: Cardiovascular Interventions, 2015, 8, e002673.	1.4	38
67	Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. New England Journal of Medicine, 2015, 373, 997-1009.	13.9	334
68	Acute Kidney Injury in Patients With Chronic Kidney Disease Undergoing Internal Carotid Artery Stent Implantation. JACC: Cardiovascular Interventions, 2015, 8, 1506-1514.	1.1	24
69	Statins and contrast-induced acute kidney injury. Coronary Artery Disease, 2014, 25, 550-551.	0.3	1
70	Novel Biomarkers for Contrast-Induced Acute Kidney Injury. BioMed Research International, 2014, 2014, 1-5.	0.9	41
71	Novel Approaches for Preventing or Limiting Events (NAPLES III) Trial: Randomised Comparison of Bivalirudin Versus Unfractionated Heparin in Patients at High Risk of Bleeding Undergoing Elective Coronary Stenting Through The Femoral Approach. Rationale and Design. Cardiovascular Drugs and Therapy, 2014, 28, 273-279.	1.3	10
72	Hydration in contrast-induced acute kidney injury. Lancet, The, 2014, 383, 1786-1788.	6.3	13

#	ARTICLE	IF	CITATIONS
73	Routine Assessment of On-Clopidogrel Platelet Reactivity and Gene Polymorphisms in Predicting Clinical Outcome Following Drug-Eluting Stent Implantation in Patients With Stable Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1166-1175.	1.1	49
74	RenalGuard system: A dedicated device to prevent contrast-induced acute kidney injury. <i>International Journal of Cardiology</i> , 2013, 168, 643-644.	0.8	11
75	The glider balloon: A useful device for the treatment of bifurcation lesions. <i>International Journal of Cardiology</i> , 2013, 168, 3208-3211.	0.8	6
76	Endothelial progenitor cells in coronary artery disease. <i>Biological Chemistry</i> , 2013, 394, 1241-1252.	1.2	7
77	Stent thrombosis in patients with chronic kidney disease. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 617-626.	0.6	0
78	The Avantgarde Carbostent in Patients Scheduled for Undelayable Noncardiac Surgery. <i>Thrombosis</i> , 2012, 2012, 1-6.	1.4	2
79	The CID Chrono, cobalt-chromium alloy carbofilm-coated coronary stent system. <i>International Journal of Cardiology</i> , 2011, 149, 199-204.	0.8	9
80	Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of Statins. <i>International Journal of Hypertension</i> , 2011, 2011, 1-12.	0.5	9
81	Nephrotoxicity of contrast media and protective effects of acetylcysteine. <i>Archives of Toxicology</i> , 2011, 85, 165-173.	1.9	41
82	Novel Approaches for Preventing or Limiting Events in Diabetic Patients (Naples-Diabetes) Trial. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 121-129.	1.4	41
83	Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II). <i>Circulation</i> , 2011, 124, 1260-1269.	1.6	217
84	Renal insufficiency following contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design. <i>EuroIntervention</i> , 2011, 6, 1117-1122.	1.4	22
85	Correlations between progression of coronary artery disease and circulating endothelial progenitor cells. <i>FASEB Journal</i> , 2010, 24, 1981-1988.	0.2	80
86	Cystatin C and Contrast-Induced Acute Kidney Injury. <i>Circulation</i> , 2010, 121, 2117-2122.	1.6	212
87	In Vivo Histological Assessment of a Spontaneous Coronary Artery Dissection. <i>Circulation</i> , 2010, 122, 1044-1046.	1.6	7
88	Novel Approaches for Preventing or Limiting Events (Naples) II Trial. <i>Journal of the American College of Cardiology</i> , 2009, 54, 2157-2163.	1.2	223
89	Recalcitrant in-stent restenosis of the celiac trunk treated by drug-eluting stent. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 873-876.	0.7	11
90	Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL). <i>Circulation</i> , 2007, 115, 1211-1217.	1.6	438